Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan + Melphalan vs Melphalan for MM ASCT
NCT01413178Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2011
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of busulfan in multiple myeloma (MM) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival at 3 years. Started Sep 2011; status: completed.
02
Drugs
busulfan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01413178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01413178.